This product is a blood lipid regulating drug of clofibric acid derivatives. It may reduce the cAMP content in liver microsomes, increase the activity of lipoprotein esterase, and decompose lipids in lipoproteins. Experimental and clinical studies have shown that this product reduces blood cholesterol and triglycerides and increases blood high-density lipoprotein. In addition, this product also has anti-platelet aggregation and anti-thrombotic effects and reduces blood uric acid.

This product is an oral selective histamine H1 receptor antagonist. It has no obvious anticholinergic and anti-5-hydroxytryptamine effects, and has a small central nervous system inhibitory effect.

It is a Class Ib antiarrhythmic drug that can inhibit sodium influx into myocardial cells, reduce the speed of phase 0 depolarization of the action potential, and shorten the effective refractory period of Purkinje fibers. In patients with normal cardiac conduction systems, mexiletine has little effect on the generation and conduction of cardiac impulses. Clinical trials have not found that mexiletine causes second-degree or third-degree atrioventricular block. Mexiletine does not prolong the duration of ventricular depolarization and repolarization, so it can be used for ventricular arrhythmias with prolonged QT intervals. The drug has antiarrhythmic, anticonvulsant and local anesthetic effects. It has a small inhibitory effect on the myocardium.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis. Bacteria have cross-resistance to rifamycin antibiotics. Rifampicin binds firmly to the β-subunit of DNA-dependent RNA polymerase, inhibiting the synthesis of bacterial RNA and preventing the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

It is a nutritional medicine that can supplement calories and improve sugar metabolism. Its metabolism in the body does not rely on the participation of insulin. It directly participates in sugar metabolism through the cell membrane without increasing blood sugar concentration. Its sweetness and heat generation are similar to those of glucose. It can be used as a sugar substitute for diabetic patients. In addition, it has the effect of inhibiting the production of ketone bodies and can reduce the production of plasma fatty acids. It can be used as a combined drug for diabetes and ketoacidosis during surgical anesthesia.